Ketisal

Ketotifen hydrogen fumarate, the active ingredient in Ketisal, is an antihistamine; mast cell stabilizer presented as an ophthalmic solution for ocular use. It is employed to relieve symptoms of allergic eye conditions in patients of all ages.

GNH USA supplies Ketisal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ketisal is used to manage ocular allergic reactions by targeting histamine‑mediated pathways.

Allergic conjunctivitis: reduces itching, redness and swelling of the eye surface. Seasonal allergic eye disease: alleviates symptoms triggered by seasonal allergens. Vernal keratoconjunctivitis: helps control chronic inflammation and discomfort in affected individuals.

Ketisal may cause ocular and systemic reactions in some patients.

Common Side Effects: - Burning or stinging sensation upon instillation. - Temporary blurred vision. - Mild eye irritation or redness. - Tearing or watery discharge. - Headache. - Dry eye sensation.

Serious or Rare Side Effects: - Persistent eye pain or severe irritation. - Significant visual acuity changes. - Allergic contact dermatitis around the eye. - Corneal ulceration. - Secondary ocular infection. - Systemic hypersensitivity reactions such as rash or swelling.

Before using Ketisal, consider the following safety measures. - Pregnancy: consult a healthcare professional, as safety data are limited. - Breastfeeding: discuss potential risks with a physician. - Contact lens wearers: remove lenses before instillation and wait before reinserting. - Pre‑existing ocular conditions: inform the prescriber of glaucoma, cataract or recent eye surgery. - Concomitant eye medications: avoid mixing unless advised by a clinician. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Ketisal may interact with other ophthalmic agents and systemic drugs.

Major Interactions (Avoid): - Concurrent use with other mast cell stabilizers may increase local irritation. - Combination with topical anesthetics can exacerbate corneal toxicity.

Moderate Interactions (Monitor Closely): - Systemic antihistamines may potentiate sedative effects if systemic absorption occurs. - Use with ocular non‑steroidal anti‑inflammatory drugs (NSAIDs) may increase risk of corneal complications. - Interaction with beta‑blocker eye drops may affect intra‑ocular pressure control. - Caution when combined with corticosteroid eye drops, as additive immunosuppression may occur.